The Conference Forum has announced that Dennis Purcell, Senior Managing Partner of Aisling Capital, will host a series of interviews with some of the top, unique life science deals of 2012 on January 8th, 2013 at the 3rd Annual New Paradigms event in San Francisco. Mr Purcell will be interviewing some of the most impressive dealmakers in biotech, including representation from the following deals:
- Annovation/Atlas Ventures/Partners Innovation Fund/The Medicines Company
- Warp Drive Bio/Sanofi/Third Rock Ventures/Greylock Partners
- GSK/J&J/Index Ventures
- Enlight’s KNODE and AstraZeneca
Valerie Bowling, Executive Director of the Conference Forum, describes the New Paradigms event, “as the only conference fully dedicated to addressing alternative sources of financing and innovative deal structures to advance R&D in the life science industry.” The program is scheduled specifically to take place in San Francisco in the second week in January when the largest gathering of life science executives and investors attend a variety of meetings and networking events.
Keynoting is Dr Raymond F. Schinazi, whose inventions have sold for more than $2 billion per year. More than 94% of HIV infected individuals take at least one of the drugs he invented. Dr. Schinazi, a Frances Winship Walter Professor at Emory University and Veterans Affairs Medical Center is going to address maintenance of control over the development of a molecule.
Chairman and Editor in Chief of BioCentury, Dr. Karen Bernstein will lead an A-list team of Biotech Leaders on what we can expect from the current status and near future of funding innovation.
The program will feature the first interactive showcase for privately-held life science companies to present in front of a cross-section of investors and obtain their feedback live on stage. The investor representation includes: Abbott Biotech Ventures, Atheneos Capital, Band of Angels, Connecticut Innovations, Frazier Healthcare, Forward Ventures, Genentech, Golden Gate Angels, Harvard Angels, MedImmune Ventures, Merck Research Ventures, Merck Serono Ventures, MPM Capital, Red Sky Partners, Skyline Ventures Symphony, Capital LLC, SR One, SV Life Sciences Advisers LLP, The Angels’ Forum, The Halo Funds, venBio and Versant Ventures.
The conference will have over 75 speakers and expects to attract 250 attendees. Partnering meeting rooms will be open throughout the conference. The event is co-sponsored by Bay Bio, the California Healthcare Institute, Women in Bio, Astia and BioCentury.
For more information on the sessions, speakers, full and partial scholarships and general registration, please visit http://www.theconferenceforum.org.
Contact Information: Ciara Healy Marketing Manager The Conference Forum [email protected] Phone: 646 350 2580
The Conference Forum